Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.22.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash $ 85,838 $ 592,053
Accounts receivable, net 1,500 500
Grant receivable 56,359 224,879
Prepaid expenses 84,629 157,493
Total current assets 228,326 974,925
Property and equipment, net 102,843 128,605
Right to use assets 384,921 489,536
Other assets:    
Patents, net 11,385 12,564
Software development costs 47,980 0
Intellectual property, net 0 176,850
Deposits, long term 44,520 44,520
Total other assets 103,885 233,934
Total assets 819,975 1,827,000
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,014,892 and $686,068, respectively 3,188,560 2,490,158
Deferred revenue, short term 34,981 63,331
Deferred revenue-grant 0 65,560
Lease liability, short term 119,733 106,290
Notes payable 221,480 21,480
Notes payable, related parties 790,110 290,110
PPP loan, short term 31,580 15,445
Total current liabilities 4,386,444 3,052,374
Long term liabilities:    
PPP loan, long term 99,860 12,555
EIDL loan, long term 74,300 74,300
Royalty obligation - net of discount of $5,854,226 and $6,331,662, related parties 2,867,874 2,390,438
Lease liability, long term 315,672 435,405
Deferred revenue, long term 37,301 72,281
Total liabilities 7,781,451 6,037,353
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 6,698,968 and 5,463,444 shares issued and outstanding as of December 31, 2021 and 2020, respectively 6,699 5,463
Common stock subscribed 100,000 100,000
Additional paid in capital 62,994,739 60,466,333
Accumulated deficit (69,966,692) (64,688,311)
Total deficit attributable to BioCorRx, Inc. (6,843,638) (4,094,899)
Non-controlling interest (117,838) (115,454)
Total deficit (6,961,476) (4,210,353)
Total liabilities and deficit 819,975 1,827,000
Series A Preferred Stock [Member]    
Deficit:    
Preferred stock value 16,000 16,000
Series B Convertible Preferred Stock    
Deficit:    
Preferred stock value $ 5,616 $ 5,616